Nanotechnology based assays for validating protein biomarkers

15 Dec

These Gyro Mark™ HT assays were also compared to the MSD platform in the analysis of vancomycin-treated rat urine samples (n=36); correlations were r = 0.97 (KIM-1, Figure 3A) and 0.87 (clusterin, Figure 3B).The rat urine samples were also tested for clusterin using a MILLIPLEX® MAP bead-based assay for the Luminex® platform (Figure 4).Table 2A These data demonstrate that our Gyro Mark™ HT toxicity assays for rat KIM-1 and clusterin, are robust and reproducible, using 1000 n L samples, and can be useful for detecting kidney damage in rat urine samples for drug development and basic research.Health insurance companies may or may not provide coverage for tumor marker tests.In this study, we determined assay performance characteristics for the Gyro Mark™ HT rat KIM-1 and Clusterin assays, and then measured these biomarkers from urine samples of rats treated with gentamicin.We compared the results to those obtained using an electrochemiluminescence assay on the Mesoscale Discovery (MSD) platform, to a traditional ELISA, and to a MILLIPLEX® MAP assay for the Luminex® platform. GYRKIM1-20K) were developed and used for biomarker quantitation, according to the protocols supplied with the kits.

Instead of just one protein, proteomic research assessing patterns in proteins can allow doctors to test thousands of proteins at once, which may reveal the groups of the most common proteins associated with different types of cancer.The National Cancer Institute's Alliance for Nanotechnology in Cancer has released a special feature paper titled Nanotechnology-Based Assays for Validating Protein Biomarkers.As the paper states, nanotechnology offers some unique diagnostic capabilities for developing highly sensitive and selective assays.We evaluated rats treated with no, low, and high doses of gentamicin, a known nephrotoxicant. Also used were the MILLIPLEX® MAP Rat Kidney Toxicity Magnetic Bead Panel 1 - Toxicity Multiplex Assay (Cat. RKTX1MAG-37K), and a traditional ELISA kit from R&D Systems.Urine samples (n=36) were collected on days 0, 3, 7, and 14. For the KIM-1 assay, we determined dynamic range, sensitivity, spike recovery, dilution linearity, intra-, and inter-assay variations of 0.015-60 ng/m L, 0.015 ng/m L, 100%, 107%, The standard curves for the Gyro Mark™ HT KIM-1 and clusterin assays were compared to the curves obtained for the same standards but using the MSD platform.